Agios Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Agios Pharmaceuticals Il CEO è Brian Goff, nominato in Aug2022, e ha un mandato di 2.33 anni. la retribuzione annua totale è $ 3.42M, composta da 23.4% di stipendio e 76.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.14% delle azioni della società, per un valore di € 2.67M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.9 anni e 7.7 anni.

Informazioni chiave

Brian Goff

Amministratore delegato

US$3.4m

Compenso totale

Percentuale dello stipendio del CEO	23.4%
Mandato del CEO	2.3yrs
Proprietà del CEO	0.1%
Durata media del management	2.9yrs
Durata media del Consiglio di amministrazione	7.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Brian Goff rispetto agli utili di Agios Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$674m
Jun 30 2024	n/a	n/a	-US$365m
Mar 31 2024	n/a	n/a	-US$353m
Dec 31 2023	US$3m	US$798k	-US$352m
Sep 30 2023	n/a	n/a	-US$220m
Jun 30 2023	n/a	n/a	-US$210m
Mar 31 2023	n/a	n/a	-US$218m
Dec 31 2022	US$12m	US$308k	-US$232m

Compensazione vs Mercato: La retribuzione totale di Brian ($USD 3.42M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.58M ).

Compensazione vs guadagni: La retribuzione di Brian è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Brian Goff (55 yo)

2.3yrs

Mandato

US$3,416,453

Compensazione

Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. since June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. since August 08, 2022. He had be...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Brian Goff	CEO & Director	2.3yrs	US$3.42m	0.14% € 2.7m
Cecilia Jones	Chief Financial Officer	2.3yrs	US$1.21m	0.035% € 684.4k
James Burns	Corporate Secretary & Chief Legal Officer	2.9yrs	US$1.93m	0.028% € 533.0k
Sarah Gheuens	Chief Medical Officer and Head of Research & Development	3.3yrs	US$2.87m	0.077% € 1.5m
Tsveta Milanova	Chief Commercial Officer	1.9yrs	US$3.73m	0.023% € 449.3k
Lewis Cantley	Founder	no data	US$333.51k	Nessun dato
Tak Mak	Founder	no data	Nessun dato	Nessun dato
Craig Thompson	Founder	no data	Nessun dato	Nessun dato
Shin-San Su	Founder	no data	Nessun dato	Nessun dato
T. Washburn	VP, Controller & Principal Accounting Officer	3.3yrs	Nessun dato	0.0014% € 27.7k
Clive Patience	Chief Technical Operations Officer	7.5yrs	Nessun dato	Nessun dato
Christopher J. Taylor	Vice President of Investor Relations & Corporate Communications	no data	Nessun dato	Nessun dato

2.9yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di 8AP è considerato esperto (durata media dell'incarico 2.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Brian Goff	CEO & Director	2.3yrs	US$3.42m	0.14% € 2.7m
Jacqualyn Fouse	Chair of the Board of Directors	7yrs	US$447.25k	0.25% € 4.8m
Jeffrey Capello	Independent Director	1.5yrs	US$663.68k	0.0035% € 67.0k
Marc Tessier-Lavigne	Member of Scientific Advisory Board	8.3yrs	US$302.85k	Nessun dato
Charles Sawyers	Member of Scientific Advisory Board	15.8yrs	Nessun dato	Nessun dato
Kaye Foster-Cheek	Lead Independent Director	10yrs	US$440.95k	0.013% € 256.3k
David Schenkein	Independent Director	15.3yrs	US$417.25k	0.83% € 16.2m
Joan Brugge	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Matthew Vander Heiden	Member of Scientific Advisory Board	16.1yrs	Nessun dato	Nessun dato
Scott Biller	Member of Scientific Advisory Board	3.9yrs	US$3.21m	Nessun dato
Cynthia Smith	Independent Director	2.3yrs	US$419.91k	0.014% € 271.2k
Ralph Deberardinis	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

7.7yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 8AP sono considerati esperti (durata media dell'incarico 7.7 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/23 06:45
Prezzo dell'azione a fine giornata	2024/12/20 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Agios Pharmaceuticals, Inc. è coperta da 32 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Peter Lawson	Barclays
George Farmer	BMO Capital Markets Equity Research
Alec Stranahan	BofA Global Research

Agios Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Recent updates

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

New minor risk - Share price stability

Investor sentiment improves as stock rises 25%

Third quarter 2024 earnings released: EPS: US$16.65 (vs US$1.64 loss in 3Q 2023)

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

New minor risk - Profitability

Second quarter 2024 earnings released: US$1.69 loss per share (vs US$1.51 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

New minor risk - Profitability

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Forecast to breakeven in 2024

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

First quarter 2024 earnings released: US$1.45 loss per share (vs US$1.47 loss in 1Q 2023)

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$6.33 loss per share (vs US$4.23 loss in FY 2022)

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Third quarter 2023 earnings released: US$1.64 loss per share (vs US$1.49 loss in 3Q 2022)

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.68 loss in 2Q 2022)

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

No longer forecast to breakeven

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Chief Commercial Officer Darrin Miles has left the company

Insufficient new directors

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Insider recently sold €158k worth of stock

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Full year 2020 earnings released: US$4.75 loss per share (vs US$6.86 loss in FY 2019)

Revenue beats expectations

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

New 90-day high: €47.53

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

New 90-day high: €40.87

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.